Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws related to its IPO and subsequent financial disclosures, which reportedly misrepresented the company's growth prospects and operational readiness [1][3]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. IPO Details - The company conducted its IPO on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Allegations of Misrepresentation - The lawsuit claims that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program, which could have a material negative impact once revealed [3]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [4]. - The Spacecraft Solutions segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [4]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [4][5].

Core Viewpoint - A class action lawsuit has been filed against Sprouts Farmers Market, Inc. for allegedly providing misleading information regarding its growth potential during the fiscal year 2025, which may have led to investor losses [5]. Group 1: Class Action Details - The class action is on behalf of purchasers of securities and sellers of put options of Sprouts Farmers Market between June 4, 2025, and October 29, 2025 [1]. - Investors who purchased securities or sold put options during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 2: Allegations Against the Company - The lawsuit claims that the defendants provided overly positive statements about Sprouts Farmers Market's growth potential while concealing material adverse facts [5]. - Specifically, the defendants expressed confidence in the company's customer base's resilience to macroeconomic pressures, suggesting that the company would benefit from a cautious consumer environment [5]. - However, the lawsuit alleges that a more cautious consumer could lead to a significant slowdown in sales growth, contradicting the positive outlook presented to investors [5]. Group 3: Law Firm Background - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, highlighting its effectiveness in representing investor interests [4].

Core Viewpoint - Anika Therapeutics, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following the release of disappointing clinical trial results for its product Hyalofast [1][3]. Group 1: Investigation Details - The law firm Kirby McInerney LLP is leading the investigation into Anika Therapeutics [1]. - The investigation focuses on whether Anika and/or its senior management engaged in unlawful practices related to the company's securities [1]. Group 2: Clinical Trial Results - On July 30, 2025, Anika announced topline results from a clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair [3]. - The trial showed consistent improvements in treated patients compared to microfracture, but did not meet its pre-specified co-primary endpoints [3]. - Factors affecting the trial results included a higher dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and a reduced evaluable sample size [3]. - Following the announcement, Anika's share price fell by $3.06, or approximately 27.42%, closing at $8.10 per share [3].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - Defendants allegedly made unauthorized design changes to the G6 and G7 systems that compromised their reliability and safety [2]. - The enhancements claimed for the G7 device were reportedly overstated, leading to potential health risks for users relying on these devices for accurate glucose readings [2]. - DexCom is accused of downplaying the severity of issues related to the G7 devices, which could result in increased regulatory scrutiny and significant legal and financial repercussions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the enhancements to the G7 device were overstated, and the true scope of issues related to the G7 devices was downplayed by the defendants [5]. - The allegations suggest that these actions subjected DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [5].

NEW YORK, Dec. 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.So what: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/moonlake-lawsuit-s ...

Core Viewpoint - A class action securities lawsuit has been filed against Firefly Aerospace Inc. due to alleged securities fraud affecting investors who purchased shares during the company's IPO and subsequent period [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals and entities that acquired Firefly common stock related to the IPO on August 7, 2025, and those who purchased Firefly securities between August 7, 2025, and September 29, 2025 [2]. Case Details - The complaint alleges that the defendants made false statements and concealed critical information, including: - Overstated demand and growth prospects for Firefly's Spacecraft Solutions offerings [3] - Overstated operational readiness and commercial viability of the Alpha rocket program [3] - The revelation of these issues would likely have a material negative impact on the company [3] - Offering documents and public statements were materially false and misleading [3] Next Steps - Investors who suffered losses during the relevant timeframe have until January 12, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. No Cost to Participants - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [4]. Why Levi & Korsinsky - The firm has a strong track record in securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint highlights significant manufacturing deficiencies in the facility dedicated to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom investors who were adversely affected by alleged securities fraud between January 8, 2024 and September 17, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/dexcom-inc-lawsuit-submission-form-2 ...